Tomorrow’s Therapeutics—Engineered, Expressed, and Scaled by Elise
At Elise Biopharma, we partner with pioneers developing the next wave of biologic innovation—from bispecific T-cell engagers and nanobodies to synthetic biology products and cell-free protein systems. These advanced modalities demand precision, adaptability, and deep scientific fluency—and our platform is built to deliver just that.
We offer specialized services for R&D-stage and preclinical clients, along with fully scalable GMP pathways forElise Biopharma specializes in emerging biologics including BiTEs, nanobodies, and cell-free protein synthesis. From ScFv bispecifics to VHH engineering and synthetic biology platforms, we offer advanced development and scalable manufacturing solutions.
clinical translation. Whether you’re engineering a BiTE, designing a cell-free system, or developing a next-gen nanobody library, Elise offers the tools, experience, and infrastructure to bring your concept to clinic.
Core Offerings
1. Bispecific T-Cell Engagers (BiTEs)
Dual-Target Precision with a GMP Pathway
Bispecific antibodies and BiTEs require advanced expression and purification strategies to maintain stability, binding specificity, and batch consistency.
Our BiTE Capabilities:
- ScFv-linker-scFv BiTEs (anti-CD3 + tumor target)
- Bispecific IgGs (CrossMab, DuoBody, DVD-Ig, and BiTE-Fc formats)
- E. coli and CHO expression systems with titer optimization
- Inclusion body handling and refolding workflows
- Multi-column purification (Protein A/G + IEC + HIC)
- Dual-potency and binding assays (e.g. CD3/CD19, CD3/BCMA)
Analytical Capabilities:
- SEC for aggregate/monomer separation
- Functional assays with T-cell co-culture
- Potency via reporter assays or cytotoxicity platforms
- CD3-binding specificity and off-target screening
Elise enables fast, scalable BiTE manufacturing with quality documentation and regulatory support for IND-enabling studies.
Synthetic Biology & Cell-Free Protein Synthesis
Biofabrication Without a Cell
Cell-free systems unlock new frontiers in protein synthesis, enabling expression of toxic, fast-degrading, or non-natural proteins.
Key Services:
- Lysate-based CFPS platforms (E. coli, wheat germ, CHO)
- DNA template design and linear expression optimization
- On-demand protein synthesis for screening, diagnostics, or rapid prototyping
- High-throughput reaction setup and scalability to milligram-level yields
- Cofactor-supplemented, energy-replenishing reaction environments
- Post-translational modification support (limited glycosylation and disulfide folding)
Applications We Support:
- Fast protein prototyping for drug screening
- Diagnostic enzymes and biosensors
- Proteins with non-canonical amino acids
- Peptides, growth factors, and toxins incompatible with in vivo hosts
Elise is among the few CDMOs offering cell-free synthesis at commercial scale, enabling a new generation of synthetic biology products.
Nanobody & VHH Development Pipelines
Compact, Stable, and Powerful Therapeutics
Nanobodies and VHHs (single-domain antibodies) are rapidly growing in therapeutic relevance due to their size, stability, and targeting versatility.
Our Nanobody Services Include:
- Phage or yeast display–based library screening
- VHH engineering, humanization, and affinity maturation
- E. coli and Pichia pastoris expression optimization
- Periplasmic expression and refolding
- High-throughput screening for solubility and affinity
- Dual- and trispecific VHH fusion formats (e.g. VHH-VHH-ScFv)
Analytical Support:
- ELISA, SPR, and BLI for affinity and kinetic profiling
- SEC-MALS for size and aggregation state
- Isoform separation and pI analysis
- Developability assessment (charge, aggregation, viscosity)
We provide full upstream and downstream development workflows, including purification strategies tailored to nanobody hydrophobicity and dimerization tendencies.
Why Elise for Emerging Modalities?
✅ Built for Flexibility
From microgram cell-free assays to clinical-scale BiTE production, Elise supports every scale with modular, project-specific infrastructure.
✅ Modalities with Depth
We don’t just “accept” emerging modalities—we understand them. Our scientists publish, prototype, and collaborate in these frontier spaces.
✅ Platform Plus Customization
We maintain platform processes for nanobodies and BiTEs but adapt them rapidly to your linker design, codon usage, or display strategy.
✅ Fast Turnaround for Discovery & Preclinical Clients
We support early innovators with fast prototyping, clone screening, and scaled-up batches for preclinical animal studies or feasibility work.
Supported Modalities
- Bispecific T-cell engagers (BiTEs)
- DuoBody, DVD-Ig, and Fc-fusion bispecifics
- VHH nanobodies (monospecific and multi-specific)
- Cell-free expressed enzymes and binders
- Toxin-based fusion constructs
- Intrabodies and intracellular binders
- Engineered scaffold proteins (e.g., DARPins, Affibodies)
- Diagnostic reagents and high-affinity biosensors
Infrastructure & Tech Overview
| Platform Area | Capability |
|---|---|
| BiTE Production | CHO and E. coli; ScFv refolding pipelines |
| Nanobody Screening | Yeast & phage display, clone ranking |
| Cell-Free Systems | Lysate prep, reaction optimization |
| Purification | Multi-column workflows, endotoxin control |
| Analytics | BLI, SEC-MALS, SPR, LC-MS |
| Regulatory | Pre-IND support, documentation, QA review |
Partner With Elise
The future of biologics will be built with new rules—and new tools. Elise Biopharma offers the expertise, flexibility, and scientific partnership needed to unlock the full potential of BiTEs, nanobodies, and synthetic biology.
Bring us your blue-sky concept.
We’ll help you express it, purify it, validate it—and scale it into something real.
.